GB2411116B - Increasing the bioavailability of alendronate by predose administration of alphacalcidol - Google Patents

Increasing the bioavailability of alendronate by predose administration of alphacalcidol

Info

Publication number
GB2411116B
GB2411116B GB0511750A GB0511750A GB2411116B GB 2411116 B GB2411116 B GB 2411116B GB 0511750 A GB0511750 A GB 0511750A GB 0511750 A GB0511750 A GB 0511750A GB 2411116 B GB2411116 B GB 2411116B
Authority
GB
United Kingdom
Prior art keywords
alphacalcidol
alendronate
bioavailability
increasing
predose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB0511750A
Other versions
GB2411116A (en
GB0511750D0 (en
Inventor
Moshe Flashner-Barak
Itzhak E Lerner
Vered Rosenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teva Pharmaceutical Industries Ltd
Original Assignee
Teva Pharmaceutical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharmaceutical Industries Ltd filed Critical Teva Pharmaceutical Industries Ltd
Publication of GB0511750D0 publication Critical patent/GB0511750D0/en
Publication of GB2411116A publication Critical patent/GB2411116A/en
Application granted granted Critical
Publication of GB2411116B publication Critical patent/GB2411116B/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
GB0511750A 2002-12-16 2003-12-16 Increasing the bioavailability of alendronate by predose administration of alphacalcidol Expired - Fee Related GB2411116B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43368502P 2002-12-16 2002-12-16
US46020603P 2003-04-02 2003-04-02
PCT/US2003/040174 WO2004058235A2 (en) 2002-12-16 2003-12-16 Method of increasing bioavailability of alendronate or other bis-phosphonate by predose administration of vitamin d derivative

Publications (3)

Publication Number Publication Date
GB0511750D0 GB0511750D0 (en) 2005-07-20
GB2411116A GB2411116A (en) 2005-08-24
GB2411116B true GB2411116B (en) 2009-04-29

Family

ID=32685268

Family Applications (1)

Application Number Title Priority Date Filing Date
GB0511750A Expired - Fee Related GB2411116B (en) 2002-12-16 2003-12-16 Increasing the bioavailability of alendronate by predose administration of alphacalcidol

Country Status (7)

Country Link
JP (3) JP2006514695A (en)
AU (1) AU2003300984A1 (en)
DE (1) DE10393906T5 (en)
GB (1) GB2411116B (en)
HK (1) HK1078802A1 (en)
IL (1) IL169127A0 (en)
WO (1) WO2004058235A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2640094C (en) * 2006-02-03 2015-04-14 Proventiv Therapeutics, Llc Treating vitamin d insufficiency and deficiency with 25-hydroxyvitamin d2 and 25-hydroxyvitamin d3
WO2007094779A1 (en) * 2006-02-14 2007-08-23 Teva Pharmaceutical Industries Ltd. Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
ES2670029T3 (en) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Therapy using vitamin D replenishment agent and vitamin D hormone replacement agent
EP2561877A1 (en) * 2006-12-20 2013-02-27 Mylan Pharmaceuticals ULC A Composition containing a Bisphosphonic Acid in combination with Vitamin D
US20100120723A1 (en) * 2006-12-20 2010-05-13 Mostafa Akbarieh Pharmaceutical composition comprising a hot-melt granulated lubricant
CN101668532B (en) 2007-04-25 2014-08-20 赛特克罗公司 Composition for treating vitamin d insufficiency and deficiency, secondary hyperparathyroidism and vitamin D responsing diseases and corresponding pharmaceutical purposes
EP3335712A1 (en) 2007-04-25 2018-06-20 Opko Renal, LLC Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
WO2008134518A2 (en) 2007-04-25 2008-11-06 Cytochroma Inc. Methods and compounds for vitamin d therapy
JP5501956B2 (en) 2007-04-25 2014-05-28 シトクロマ インコーポレイテッド Controlled release oral composition containing a vitamin D compound and a waxy carrier
US8962239B2 (en) 2008-04-02 2015-02-24 Opko Renal, Llc Methods useful for vitamin D deficiency and related disorders
KR102125424B1 (en) 2010-03-29 2020-06-22 사이토크로마 인코포레이티드 Methods and compositions for reducing parathyroid levels
KR101847947B1 (en) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 Stabilized modified release vitamin d formulation
AU2015298858A1 (en) 2014-08-07 2017-03-02 Opko Ireland Global Holdings Ltd. Adjunctive therapy with 25-hydroxyvitamin D
BR112018069727A2 (en) 2016-03-28 2019-02-05 Opko Ireland Global Holdings Ltd vitamin d treatment methods
CN109364034B (en) * 2018-11-26 2021-05-04 正大制药（青岛）有限公司 Calcitriol preparation and preparation method thereof
CN116211818B (en) * 2023-03-10 2024-04-09 菲洋生物科技(吉林)有限公司 Tablet containing alendronate sodium and preparation method thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028564A1 (en) * 1999-10-20 2001-04-26 Yuyu Industrial Co., Ltd. Pharmaceutical compositions and preparations for treatment of metabolic bone disease
WO2003007916A1 (en) * 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001028564A1 (en) * 1999-10-20 2001-04-26 Yuyu Industrial Co., Ltd. Pharmaceutical compositions and preparations for treatment of metabolic bone disease
WO2003007916A1 (en) * 2001-07-17 2003-01-30 Teva Pharmaceutical Industries Ltd. Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Erben R G et al, Journal of Bone and Mineral Research, (2002), 17(8), 1498-1511 *
Frediani B et al, Clinical Drug Investigation, (1998), 15(3), 235-244 *
Gertz B et al, Clinical Pharmacology & Therapeutics, (1995), 58(3), 288-298 *
Malavolta N et al, International Journal of Tissue Reactions, (1999), 21(2), 51-59 *
Nasud T et al, Annals of the Rheumatic Diseases, (1998), 57(6), 346-349 *
Nuti R et al, Clinical Drug Investigation, (2000), 19(1), 55-61 *

Also Published As

Publication number Publication date
JP2014205711A (en) 2014-10-30
DE10393906T5 (en) 2006-01-12
JP2011241221A (en) 2011-12-01
JP2006514695A (en) 2006-05-11
IL169127A0 (en) 2009-02-11
WO2004058235A3 (en) 2005-02-24
AU2003300984A8 (en) 2004-07-22
GB2411116A (en) 2005-08-24
GB0511750D0 (en) 2005-07-20
WO2004058235A2 (en) 2004-07-15
AU2003300984A1 (en) 2004-07-22
HK1078802A1 (en) 2006-03-24

Similar Documents

Publication Publication Date Title
HK1078802A1 (en) Increasing the bioavailability of alendronate by predose administration alphacalcidol
GB0218625D0 (en) Pharmaceutical compounds
AU2003244650A8 (en) Medicinal compounds
GB0225540D0 (en) Medicinal compounds
GB0204719D0 (en) Medicinal compounds
GB0220730D0 (en) Medicinal compounds
GB0225030D0 (en) Medicinal compounds
GB0215775D0 (en) Pharmaceutical compounds
HK1075936A1 (en) Vaccine for the prevention of malaria
EP1617847A4 (en) Methods for the controlled delivery of pharmacologically active compounds
GB0220740D0 (en) Administration of a system
ITRM20050030A1 (en) PROCEDURE FOR THE SYNCHRONIZED ACTIVATION OF A PLURALITY OF ELECTRONIC CAMERAS.
GB0204392D0 (en) Pharmaceutical compound
GB0328040D0 (en) Pharmaceutical uses of bisphosphonates
GB0310361D0 (en) Pharmaceutical compound
GB0219897D0 (en) Pharmaceutically active compounds
GB0219893D0 (en) Pharmaceutically active compounds
ZA200204577B (en) Formulations of erytromycin derivatives with improved bioavailability.
GB0424063D0 (en) Administration system
GB0212462D0 (en) Pharmaceutical compound
GB0204391D0 (en) Pharmaceutical compound
GB0212459D0 (en) Pharmaceutical compound
GB0219895D0 (en) Pharmaceutically active compounds
GB0207532D0 (en) A novel method for the administration of secretin
GB0215939D0 (en) Pharmaceutical compounds

Legal Events

Date Code Title Description
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1078802

Country of ref document: HK

R108 Alteration of time limits (patents rules 1995)

Free format text: EXTENSION ALLOWED

Effective date: 20090318

Free format text: EXTENSION APPLICATION

Effective date: 20090311

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1078802

Country of ref document: HK

PCNP Patent ceased through non-payment of renewal fee

Effective date: 20151216